News Articles for Argenica Therapeutics

Three Perth pharmaceutical companies will take a share of a $12 million funding injection by the federal government to develop Australian-made heart disease and diabetes treatments.

Perth-based neurological drug developer Argenica Therapeutics has been knocked back by the US Food and Drug Administration, dashing hopes its US clinical trials would soon start.

Shares in Argenica Therapeutics were down by 13 per cent on Friday morning, despite the biotechnology technology announcing it would raise $12 million in order to complete its second phase trial of its ARG 007 drug in ischaemic stroke patients.

Perth biotech company Argenica Therapeutics' drug, which is designed to reduce brain tissue death following a stroke, will be administrated at two local hospitals in a nationwide trial.

Our board moves wrap includes Dianne Angus, Geoff Pocock, Andrew Chapman, Tod McGrouther, Gaurav Gupta, Mark Licciardo, Joel Ives, Karen Logan, Joan Dabon, Harry Spindler, Dan Robinson, Stephen Parker, Ross Walker, Stephen Carter, Grant Lukey, Rhett Morson, Bruce Rathie, Alec PIsmiris, Geoff Stalley, Kenneth Hall, Cathy Moises, and Brady Hall.

Our weekly appointments wrap includes Graeme Morissey, Celina Chew, Jason Leeder, Nolan Hunter, Carol Innes, Pennee Osmond, Katie Winterbourne, Brooke Draper, Robert Taylor, Pat Furlong and Brian Rafferty.

Our board moves wrap includes Peter Huston, John Welborn, Ian Middlemas, Samantha South, and Benjamin Jarvis.

The state government has awarded $4.3 million to nine health and medical projects, including developing new therapy for liver cancer and delaying Alzheimer's disease progression.

Perth-based biotechnology company Argenica Therapeutics has secured a $1.2 million grant from the Federal Government.

Our board moves wrap includes Liz Dallimore, Errol Turner, Michael Jordon, Melissa Chapman, Catherine Grant-Edwards, Neil Hutchison, Steve Brockhurst, Karen O'Neill, Darryl Abotomey, Joe D'Addio, Kelly Moore, Jason Livingstone, Trevor Matthews, Bill McKenzie, Dougal Ferguson, and Sylvia Moss.

A Perron Institute spinout focused on reducing brain damage caused by strokes listed on the ASX this morning, with its share price rising 50 per cent.

The Perron Institute is kicking commercial goals, courtesy of big sales royalties and a planned ASX listing.

Shares in recruitment firm Hiremii dropped in value by close to 30 per cent today following an overall slump for tech stocks on the ASX.